Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pulmonary Hypertension
Biotech
Roivant unveils new ‘vant’ to advance Bayer hypertension med
Matt Gline is back with a new ‘vant,’ after the Roivant CEO paid Bayer $14 million upfront for the rights to a phase 2-ready hypertension drug.
James Waldron
Sep 10, 2024 7:57am
Gossamer touts phase 2 win but investors are wary
Dec 6, 2022 11:09am
ECG-enhancing AI scores FDA breakthrough nod
May 27, 2022 11:27am
